3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
2
Other solid neoplasm
2
Gastrointestinal
2
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Gastrointestinal Stromal Tumors
17
Sarcoma
6
Sarcoma, Ewing
5
Osteosarcoma
5
Neoplasm Metastasis
4
Rhabdomyosarcoma
3
Colorectal Neoplasms
3
Mesothelioma, Malignant
2
Hemangiosarcoma
2
Chondrosarcoma
2
Bone Neoplasms
2
Wilms Tumor
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
regorafenib
2
Doxorubicin
2
Cyclophosphamide
2
Cisplatin
2
tislelizumab
1
tazemetostat
1
sodium thiosulfate
1
entinostat
1
alanosine
1
X-Rays
1
Tamoxifen
1
Specimen Handling
1
Radiotherapy
1
Platinum
1
Magnetic Resonance Spectroscopy
1
Hyperthermic Intraperitoneal Chemotherapy
1
Fentanyl
1
Etoposide
1
Erlotinib Hydrochloride
1
Cytoreduction Surgical Procedures
1
Clinical Trials, Phase II as Topic
1
Celecoxib
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
regorafenib
×
Sarcoma
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled